These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23674084)

  • 1. Comment on 'High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer'.
    Ho-Yen C; Bowen RL; Kermorgant S; Jones JL
    Br J Cancer; 2013 May; 108(10):2195-6. PubMed ID: 23674084
    [No Abstract]   [Full Text] [Related]  

  • 2. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.
    Zagouri F; Bago-Horvath Z; Rössler F; Brandstetter A; Bartsch R; Papadimitriou CA; Dimitrakakis C; Tsigginou A; Papaspyrou I; Giannos A; Dimopoulos MA; Filipits M
    Br J Cancer; 2013 Mar; 108(5):1100-5. PubMed ID: 23422757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-Negative Breast Cancers.
    Gao HF; Yang CQ; Cheng MY; Zhu T; Yang M; Zhang LL; Wang K
    Clin Breast Cancer; 2018 Oct; 18(5):e961-e966. PubMed ID: 29880407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
    Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
    Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel 3-Dimensional Co-culture Method Reveals a Partial Mesenchymal to Epithelial Transition in Breast Cancer Cells Induced by Adipocytes.
    Pallegar NK; Garland CJ; Mahendralingam M; Viloria-Petit AM; Christian SL
    J Mammary Gland Biol Neoplasia; 2019 Mar; 24(1):85-97. PubMed ID: 30474817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
    Armstrong AJ; Marengo MS; Oltean S; Kemeny G; Bitting RL; Turnbull JD; Herold CI; Marcom PK; George DJ; Garcia-Blanco MA
    Mol Cancer Res; 2011 Aug; 9(8):997-1007. PubMed ID: 21665936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.
    González-Martínez S; Pérez-Mies B; Pizarro D; Caniego-Casas T; Cortés J; Palacios J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.
    Aloia A; Petrova E; Tomiuk S; Bissels U; Déas O; Saini M; Zickgraf FM; Wagner S; Spaich S; Sütterlin M; Schneeweiss A; Reitberger M; Rüberg S; Gerstmayer B; Agorku D; Knöbel S; Terranegra A; Falleni M; Soldati L; Sprick MR; Trumpp A; Judde JG; Bosio A; Cairo S; Hardt O
    Breast Cancer Res; 2015 Nov; 17(1):146. PubMed ID: 26607327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.
    Krawczyk N; Meier-Stiegen F; Banys M; Neubauer H; Ruckhaeberle E; Fehm T
    Biomed Res Int; 2014; 2014():415721. PubMed ID: 24895575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of histone chaperone APLF associate with breast cancer.
    Majumder A; Syed KM; Mukherjee A; Lankadasari MB; Azeez JM; Sreeja S; Harikumar KB; Pillai MR; Dutta D
    Mol Cancer; 2018 Mar; 17(1):76. PubMed ID: 29580241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.
    Hudson J; Ha JR; Sabourin V; Ahn R; La Selva R; Livingstone J; Podmore L; Knight J; Forrest L; Beauchemin N; Hallett M; Park M; Ursini-Siegel J
    Mol Cell Biol; 2014 Oct; 34(19):3689-701. PubMed ID: 25071152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Na+/H+ exchanger NHE1 regulation modulates metastatic potential and epithelial-mesenchymal transition of triple-negative breast cancer cells.
    Amith SR; Wilkinson JM; Fliegel L
    Oncotarget; 2016 Apr; 7(16):21091-113. PubMed ID: 27049728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Proteins of Epithelial-Mesenchymal Transition and Some Components of VEGF Signaling Pathway in Breast Cancer.
    Scherbakov AM; Gershtein ES; Korotkova EA; Ovchinnikova LK; Ovsii OG; Ermilova VD; Gens GP; Kushlinskii NE
    Bull Exp Biol Med; 2016 Apr; 160(6):802-6. PubMed ID: 27165081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronan synthase 2 is an adverse prognostic marker in androgen receptor-negative breast cancer.
    Zhang H; Tsang JY; Ni YB; Chan SK; Chan KF; Cheung SY; Tse GM
    J Clin Pathol; 2016 Dec; 69(12):1055-1062. PubMed ID: 27169756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
    Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
    Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGK1 is a Potential Survival Biomarker and Invasion Promoter by Regulating the HIF-1α-Mediated Epithelial-Mesenchymal Transition Process in Breast Cancer.
    Fu D; He C; Wei J; Zhang Z; Luo Y; Tan H; Ren C
    Cell Physiol Biochem; 2018; 51(5):2434-2444. PubMed ID: 30537744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.